These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

67 related articles for article (PubMed ID: 19960441)

  • 1. Human papillomavirus testing and cervical cytology in primary screening for cervical cancer among women in rural China: comparison of sensitivity, specificity, and frequency of referral.
    Moy LM; Zhao FH; Li LY; Ma JF; Zhang QM; Chen F; Song Y; Hu SY; Balasubramanian A; Pan QJ; Koutsky L; Zhang WH; Lim JM; Qiao YL; Sellors JW
    Int J Cancer; 2010 Aug; 127(3):646-56. PubMed ID: 19960441
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of HPV test versus conventional and automation-assisted Pap screening as potential screening tools for preventing cervical cancer.
    Nieminen P; Vuorma S; Viikki M; Hakama M; Anttila A
    BJOG; 2004 Aug; 111(8):842-8. PubMed ID: 15270934
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of several screening approaches for detection of cervical lesions in rural Shandong, China.
    Zong LJ; Zhang YZ; Yang XS; Jiang J; Cui BX; Qiao YB; Li L; Jiang K; Zhang WJ; Kong BH; Shen K
    Asian Pac J Cancer Prev; 2015; 16(5):1907-12. PubMed ID: 25773843
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effectiveness of VIA, Pap, and HPV DNA testing in a cervical cancer screening program in a peri-urban community in Andhra Pradesh, India.
    Gravitt PE; Paul P; Katki HA; Vendantham H; Ramakrishna G; Sudula M; Kalpana B; Ronnett BM; Vijayaraghavan K; Shah KV;
    PLoS One; 2010 Oct; 5(10):e13711. PubMed ID: 21060889
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence regarding human papillomavirus testing in secondary prevention of cervical cancer.
    Arbyn M; Ronco G; Anttila A; Meijer CJ; Poljak M; Ogilvie G; Koliopoulos G; Naucler P; Sankaranarayanan R; Peto J
    Vaccine; 2012 Nov; 30 Suppl 5():F88-99. PubMed ID: 23199969
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A notable accessory screening program for detection of cervical intraepithelial neoplasia.
    Tsai HT; Tsai YM; Yang SF; Lee CH; Lin LY; Lee S; Wu MT
    Pathol Biol (Paris); 2009 Sep; 57(6):477-82. PubMed ID: 18586410
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analysis for Pap smear screening and human papillomavirus DNA testing and vaccination.
    Chen MK; Hung HF; Duffy S; Yen AM; Chen HH
    J Eval Clin Pract; 2011 Dec; 17(6):1050-8. PubMed ID: 21679279
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Risk assessment and clinical impact of liquid-based cytology, oncogenic human papillomavirus (HPV) DNA and mRNA testing in primary cervical cancer screening (the FASE study).
    Monsonego J; Hudgens MG; Zerat L; Zerat JC; Syrjänen K; Smith JS
    Gynecol Oncol; 2012 Apr; 125(1):175-80. PubMed ID: 22233689
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Study on the value assessment of various screening programs regarding cervical cancer screening strategy in the rural areas of China].
    Li LY; Qiao ZQ; Zhang MF; Yang JP; Bao YP; An YT; Lei J; Xiong NH; Yu XH; Zhang X; Pan QJ; Qiao YL
    Zhonghua Liu Xing Bing Xue Za Zhi; 2007 Oct; 28(10):964-7. PubMed ID: 18399140
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomized controlled trial of human papillomavirus testing versus Pap cytology in the primary screening for cervical cancer precursors: design, methods and preliminary accrual results of the Canadian cervical cancer screening trial (CCCaST).
    Mayrand MH; Duarte-Franco E; Coutlée F; Rodrigues I; Walter SD; Ratnam S; Franco EL;
    Int J Cancer; 2006 Aug; 119(3):615-23. PubMed ID: 16572425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Abbott RealTime High Risk HPV test is a clinically validated human papillomavirus assay for triage in the referral population and use in primary cervical cancer screening in women 30 years and older: a review of validation studies.
    Poljak M; Oštrbenk A
    Acta Dermatovenerol Alp Pannonica Adriat; 2013; 22(2):43-7. PubMed ID: 23836358
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Application of liquid-based cytology and high-risk human papillomavirus DNA detection in cervical lesion screening].
    Wu D; Ding L; Wu JH; Li ZN
    Nan Fang Yi Ke Da Xue Xue Bao; 2007 Sep; 27(9):1421-3. PubMed ID: 17884792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Performance of visual inspection with acetic acid and human papillomavirus testing for detection of high-grade cervical lesions in HIV positive and HIV negative Tanzanian women.
    Dartell MA; Rasch V; Iftner T; Kahesa C; Mwaiselage JD; Junge J; Gernow A; Ejlersen SF; Munk C; Kjaer SK
    Int J Cancer; 2014 Aug; 135(4):896-904. PubMed ID: 24391021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of visual inspection with acetic acid (VIA), Lugol's iodine (VILI), cervical cytology and HPV testing as cervical screening tools in Latin America. This report refers to partial results from the LAMS (Latin AMerican Screening) study.
    Sarian LO; Derchain SF; Naud P; Roteli-Martins C; Longatto-Filho A; Tatti S; Branca M; Erzen M; Serpa-Hammes L; Matos J; Gontijo R; Bragança JF; Lima TP; Maeda MY; Lörincz A; Dores GB; Costa S; Syrjänen S; Syrjänen K
    J Med Screen; 2005; 12(3):142-9. PubMed ID: 16156945
    [TBL] [Abstract][Full Text] [Related]  

  • 15. History of high-risk HPV and Pap test results in a large cohort of patients with invasive cervical carcinoma: experience from the largest women's hospital in China.
    Tao X; Griffith CC; Zhou X; Wang Z; Yan Y; Li Z; Zhao C
    Cancer Cytopathol; 2015 Jul; 123(7):421-7. PubMed ID: 25955972
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Human papillomavirus testing for primary screening of cervical cancer precursors.
    Ratnam S; Franco EL; Ferenczy A
    Cancer Epidemiol Biomarkers Prev; 2000 Sep; 9(9):945-51. PubMed ID: 11008913
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Screening test results associated with cancer diagnoses in 287 women with cervical squamous cell carcinoma.
    Li Z; Austin RM; Guo M; Zhao C
    Arch Pathol Lab Med; 2012 Dec; 136(12):1533-40. PubMed ID: 22900617
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cost-effectiveness analysis of cervical cancer prevention based on a rapid human papillomavirus screening test in a high-risk region of China.
    Levin CE; Sellors J; Shi JF; Ma L; Qiao YL; Ortendahl J; O'Shea MK; Goldie SJ
    Int J Cancer; 2010 Sep; 127(6):1404-11. PubMed ID: 20049838
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Tuberculosis and oncogenic HPV: potential co-infections in women at high-risk of cervical cancer in rural China.
    Zhao FH; Varanasi AP; Cunningham CA; Graubard BI; Hu SY; Chen F; Barrett CJ; Qiao YL; Forman MR
    Asian Pac J Cancer Prev; 2011; 12(6):1409-15. PubMed ID: 22126473
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Early detection of cervical cancer in Germany: evidence and implementation].
    Seifert U; Klug SJ
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2014 Mar; 57(3):294-301. PubMed ID: 24562703
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 4.